{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:28:59Z","timestamp":1792031339499,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00c3\u00a9bec - Sant\u00c3\u00a9","doi-asserted-by":"publisher","award":["FRSQ5227"],"award-info":[{"award-number":["FRSQ5227"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP210232"],"award-info":[{"award-number":["MOP210232"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN-139151"],"award-info":[{"award-number":["SMN-139151"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP135260"],"award-info":[{"award-number":["MOP135260"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00c3\u00a9bec - Sant\u00c3\u00a9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.amepre.2020.01.024","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T03:02:21Z","timestamp":1589857341000},"page":"845-853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs"],"prefix":"10.1016","volume":"58","author":[{"given":"Nanor","family":"Minoyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea A.","family":"Artenie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-\u00c8ve","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amepre.2020.01.024_bib0001","series-title":"Global health sector strategy on viral hepatitis 2016-2021","year":"2016"},{"issue":"1","key":"10.1016\/j.amepre.2020.01.024_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","article-title":"Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness","volume":"25","author":"MacArthur","year":"2014","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.amepre.2020.01.024_bib0003","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.amepre.2020.01.024_bib0004","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"issue":"17","key":"10.1016\/j.amepre.2020.01.024_bib0005","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1503\/cmaj.181506","article-title":"Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs","volume":"191","author":"Artenie","year":"2019","journal-title":"CMAJ"},{"key":"10.1016\/j.amepre.2020.01.024_bib0006","series-title":"Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence","year":"2007"},{"issue":"11","key":"10.1016\/j.amepre.2020.01.024_bib0007","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/j.1360-0443.2011.03515.x","article-title":"The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence","volume":"106","author":"Turner","year":"2011","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.amepre.2020.01.024_bib0008","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ije\/dyt243","article-title":"Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis","volume":"43","author":"Aspinall","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"9","key":"10.1016\/j.amepre.2020.01.024_bib0009","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1007\/s10461-013-0593-y","article-title":"Effectiveness of structural-level needle\/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review","volume":"17","author":"Abdul-Quader","year":"2013","journal-title":"AIDS Behav"},{"issue":"suppl 3","key":"10.1016\/j.amepre.2020.01.024_bib0010","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/01.aids.0000192066.86410.8c","article-title":"Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001","volume":"19","author":"Des Jarlais","year":"2005","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.amepre.2020.01.024_bib0011","doi-asserted-by":"crossref","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"10.1016\/j.amepre.2020.01.024_bib0012","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2017.10.010","article-title":"Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe","volume":"68","author":"Fraser","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.amepre.2020.01.024_bib0013","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.drugpo.2012.07.006","article-title":"Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland","volume":"23","author":"Allen","year":"2012","journal-title":"Int J Drug Policy"},{"issue":"11","key":"10.1016\/j.amepre.2020.01.024_bib0014","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/add.14267","article-title":"Modeling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland","volume":"113","author":"Fraser","year":"2018","journal-title":"Addiction"},{"issue":"suppl 2","key":"10.1016\/j.amepre.2020.01.024_bib0015","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.amepre.2020.01.024_bib0016","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/add.14217","article-title":"Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?","volume":"113","author":"Ward","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.amepre.2020.01.024_bib0017","series-title":"Surveillance des maladies infectieuses chez les utilisateurs de drogue par injection - \u00e9pid\u00e9miologie du VIH de 1995 \u00e0 2016 - \u00c9pid\u00e9miologie du VHC de 2003 \u00e0 2016","first-page":"143","author":"Leclerc","year":"2018"},{"issue":"20","key":"10.1016\/j.amepre.2020.01.024_bib0018","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1128\/JVI.01083-08","article-title":"Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells","volume":"82","author":"Badr","year":"2008","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.amepre.2020.01.024_bib0019","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/aje\/kwq479","article-title":"Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in Montreal, Canada: a 16-year longitudinal study","volume":"173","author":"Bruneau","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.amepre.2020.01.024_bib0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ije\/28.3.514","article-title":"The validity of drug users\u2019 self-reports in a non-treatment setting: prevalence and predictors of incorrect reporting methadone treatment modalities","volume":"28","author":"Langendam","year":"1999","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.amepre.2020.01.024_bib0021","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"J Addict Med"},{"key":"10.1016\/j.amepre.2020.01.024_bib0022","series-title":"Drug Misuse and Dependence: UK Guidelines on Clinical Management","year":"2017"},{"key":"10.1016\/j.amepre.2020.01.024_bib0023","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.amepre.2020.01.024_bib0024","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/biomet\/77.1.147","article-title":"Martingale-based residuals for survival models","volume":"77","author":"Therneau","year":"1990","journal-title":"Biometrika"},{"issue":"1\u20132","key":"10.1016\/j.amepre.2020.01.024_bib0025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.drugalcdep.2012.05.018","article-title":"Injection of drug residue as a potential risk factor for HCV acquisition among Montreal young injection drug users","volume":"126","author":"Roy","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.amepre.2020.01.024_bib0026","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1360-0443.2007.01912.x","article-title":"Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users","volume":"102","author":"Van Den Berg","year":"2007","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.amepre.2020.01.024_bib0027","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1360-0443.2009.02888.x","article-title":"Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews","volume":"105","author":"Palmateer","year":"2010","journal-title":"Addiction"},{"issue":"5B","key":"10.1016\/j.amepre.2020.01.024_bib0028","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-9343(97)89441-7","article-title":"Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview","volume":"102","author":"Bell","year":"1997","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.amepre.2020.01.024_bib0029","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/jir196","article-title":"A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.amepre.2020.01.024_bib0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0376-8716(98)00028-3","article-title":"Self-report among injecting drug users: a review","volume":"51","author":"Darke","year":"1998","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.amepre.2020.01.024_bib0031","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.amepre.2020.01.024_bib0032","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cid\/ciw676","article-title":"Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies","volume":"64","author":"Sarrazin","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2020.01.024_bib0033","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2016.05.012","article-title":"Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs","volume":"165","author":"Weir","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.amepre.2020.01.024_bib0034","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11904-017-0358-8","article-title":"HCV cure and reinfection among people with HIV\/HCV coinfection and people who inject drugs","volume":"14","author":"Martinello","year":"2017","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"5","key":"10.1016\/j.amepre.2020.01.024_bib0035","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","article-title":"Hepatitis C reinfection after sustained virological response","volume":"64","author":"Midgard","year":"2016","journal-title":"J Hepatol"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379720300908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379720300908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:54:08Z","timestamp":1760082848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379720300908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0749379720300908"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2020.01.024","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2020.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine.","name":"copyright","label":"Copyright"}]}}